Co-Diagnostics, Inc. CoPrimer™ Platform Featured at PAG XXVII Conference
Presentation coincided with launch of a private-label CoPrimer product
The public introduction of a novel, one-step SNP genotyping methodology with scalable multiplex capability followed a joint development project over the past year to test the performance of CoPrimers in multiplexed reactions. It also coincided with a private label CoPrimer product launch by a global leader in the design and manufacture of sophisticated polymerase chain reaction (PCR) reagents and other custom oligonucleotide-based tools for applied markets. The patented structure of CoPrimers makes the platform ideal for a wide array of PCR applications, including infectious diseases, multiplexing of PCR reactions, SNP/SNV detection, agricultural and food supply chain uses, liquid biopsy, and next generation sequencing.
Marketing for the private labeled product includes its ability to allow assay interchangeability, overcoming a common shortfall of traditional multiplex PCR technologies, and to enable multiplex PCR while maintaining workflow flexibility. This flexibility supports a much broader range of applications including gene expression, adventitious presence (AP) testing, copy number variation, and SNP differentiation. The product can be designed with a range of fluorescent dyes to fit most PCR detection instruments on the market and allows customers to generate twice as much data per reaction, which reduces overall cost of operations.
More information about the product, including contact information for labs to learn how they can reduce cost and improve efficiency, can be found here.
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances.Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Co-Diagnostics Investor Relations